INS and diabetes mellitus: The first one is that patients with diabetes may have a higher likelihood of receiving insulin therapy in comparison to patients without the disease, possibly attenuating the rise in plasma free fatty acids (FFA) as well as providing antithrombotic properties associated with its use (Capes et al., 2000; Jain et al., 1993; Malmberg et al., 1999).